
HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Targeting HER2 mutations with TKIs
Panelists note potential for agents like zongertinib if mutations match lung cancer targets and show gastric responders in phase I.
Play episode from 16:02
Transcript


